Our study and others’ work suggest that multi-axis metabolic targeting (e.g., simultaneous inhibition of ASNS and glutaminase, or ASNS and autophagy) may provide synergistic benefit and prevent resistance by starving cancer cells of compensatory pathways. The gene discussed is ASNS; the disease is cancer.